摘要
目的:观察还原型谷胱甘肽对原发性肝癌患者经射频消融术(RFA)术后肝损害的疗效及安全性。方法:选择肝功能Child-Pugh分级正常、准备行RFA的原发性肝癌患者76例,随机分为治疗组与对照组,各38例。对照组用肌苷、维生素C等常规护肝药物治疗;治疗组在肌苷、维生素C等常规护肝药的基础上,加用还原型谷胱甘肽(1.8g加入5%葡萄糖注射液250mL)。2组均在RFA术前3天用药,静脉滴注,每日1次,连用3d;术后当天开始用药,静脉滴注,每日1次,连用7d。分别于RFA术后第1天、第7天、第15天测定血总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总蛋白(SP)、白蛋白(A)、血小板(PLT)、凝血酶原时间(PT);记录RFA术后不良反应的发生率。结果:RFA术后2组肝功能均有异常,但治疗组术后第15天TBIL、ALT和AST明显低于对照组(P<0.01),SP、A比较差异无统计学意义(P>0.05)。结论:还原型谷胱甘肽对原发性肝癌患者RFA术后肝损害有显著的保护作用,可减轻RFA副反应。
OBJECTIVE: To observe the therapeutic efficacy and safety of atomolam in the treatment of liver injury in primary hepatic carcinoma patients after radiofrequency ablation (RFA). METHODS: 76 primary hepatic carcinoma patients with normal liv- er function undergoing RFA were randomly divided into treatment group and control group with 38 patients in each group. Control group was given camine, vitamin C and other drugs for liver-protective treatment: treatment group was additionally given atomol- am 1.8 g added into 5% glucose injection 250 mL on the basis of control group. 2 groups were given medicine 3 days before RFA, i.v. gtt, once a day for consecutive 3 days: they were given medicine on same day of operation, i.v. gtt, once a day for consecu- tive 7 days. The liver function markers (serum levels of TBIL, ALT, AST, SP, A, PLT and PT) of 2 groups were detected and compared in 1 day, 7 days and 15 days after RFA respectively. The incidences of adverse drug reactions after RFA were recorded. RESULTS: After RFA, the liver function became abnormal gradually in both 2 groups, but the serum levels of ALT, AST and TBIL ~n treatment group were lower than control group significantly in 15 days after RFA (P〈0.01), while there was no signifi- cant difference in levels of SP and A (P〉0.05). CONCLUSION: Atomolan has some protective effect on liver function in primary hepatic carcinoma patients, and relieves some side effect induced by RFA.
出处
《中国药房》
CAS
CSCD
2012年第38期3601-3603,共3页
China Pharmacy
基金
教育部"高等学校青年骨干教师国内访问学者项目"(960)
关键词
还原型谷胱甘肽
原发性肝癌
射频消融术
肝功能
Atomolan
Primary hepatic carcinoma
Radiofrequency ablation
Liver function